Charles Schwab
NERV icon

Charles Schwab’s Minerva Neurosciences NERV Stock Holding History

Charles Schwab’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$631K Buy
113,625
+82,625
+267% +$448K ﹤0.01% 3170
2026
Q1 		$187K Buy
+31,000
New +$178K ﹤0.01% 3310
2021
Q2 		– Sell
-9,871
Closed -$231K – 3498
2021
Q1 		$231K Buy
9,871
+27
+0.3% +$675 ﹤0.01% 3301
2020
Q4 		$185K Hold
9,844
– – ﹤0.01% 3266
2020
Q3 		$251K Hold
9,844
– – ﹤0.01% 3104
2020
Q2 		$285K Buy
9,844
+703
+8% +$41.2K ﹤0.01% 3068
2020
Q1 		$441K Buy
9,141
+17
+0.2% +$1.03K ﹤0.01% 2758
2019
Q4 		$519K Buy
9,124
+398
+5% +$17.6K ﹤0.01% 2808
2019
Q3 		$541K Buy
8,726
+170
+2% +$9.63K ﹤0.01% 2768
2019
Q2 		$386K Hold
8,556
– – ﹤0.01% 2931
2019
Q1 		$539K Buy
8,556
+360
+4% +$21.6K ﹤0.01% 2736
2018
Q4 		$442K Hold
8,196
– – ﹤0.01% 2810
2018
Q3 		$823K Hold
8,196
– – ﹤0.01% 2681
2018
Q2 		$541K Buy
8,196
+2,283
+39% +$139K ﹤0.01% 2780
2018
Q1 		$296K Hold
5,913
– – ﹤0.01% 2884
2017
Q4 		$287K Sell
5,913
-1,212
-17% -$60.1K ﹤0.01% 2890
2017
Q3 		$434K Buy
7,125
+2,800
+65% +$161K ﹤0.01% 2759
2017
Q2 		$307K Hold
4,325
– – ﹤0.01% 2854
2017
Q1 		$281K Hold
4,325
– – ﹤0.01% 2840
2016
Q4 		$407K Buy
4,325
+1,200
+38% +$122K ﹤0.01% 2726
2016
Q3 		$353K Hold
3,125
– – ﹤0.01% 2735
2016
Q2 		$256K Buy
+3,125
New +$199K ﹤0.01% 2844

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's NERV Position: Q2 2026 in Review

Charles Schwab increased its Minerva Neurosciences (NERV) stake by 267% in Q2 2026, buying an estimated $448K and bringing the position to 113,625 shares worth $631K. The position accounts for ﹤0.01% of the portfolio, ranked #3170.

Charles Schwab first reported a position in NERV in Q2 2016 and has held it in 22 quarters since. The position peaked at $823K in Q3 2018. 60 funds tracked by Wall St. Rank hold NERV as of Q2 2026.

  • Charles Schwab held 113,625 shares of Minerva Neurosciences worth $631K as of Q2 2026.
  • Charles Schwab bought 82,625 Minerva Neurosciences shares in Q2 2026, an estimated $448K.
  • Minerva Neurosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3170 holding.
  • Charles Schwab first reported a position in Minerva Neurosciences in Q2 2016 and has held it in 22 quarters since.
  • Charles Schwab's Minerva Neurosciences position peaked at $823K in Q3 2018.
  • 60 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.